Effects of the rate of discontinuing lithium maintenance treatment in bipolar disorders

Journal of Clinical Psychiatry

Volumn 57, Issue 10, 1996, Pages 441-448

  Baldessarini, Ross J ^a,e   Tondo, Leonardo ^a,b   Faedda, Gianni L ^c   Suppes, Trisha R ^d   Floris, Gianfranco ^b   Rudas, Nereide ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c Lucio Bini Psychiatric Center   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LITHIUM;

ADULT; ARTICLE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANIC DEPRESSIVE PSYCHOSIS; PRIORITY JOURNAL; REMISSION; SURVIVAL;

EID: 0029845056     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v57n1001     Document Type: Article

References (36)

1. Cade JFJ. Lithium salts in the treatment of psychotic excitement. Med J Aust 1949;36:349-352
2. Baastrup PC, Poulsen JC, Schou M, et al. Prophylactic lithium: double-blind discontinuation in manic-depressive and recurrent depressive disorders. Lancet 1970;2:326-330
3. Suppes T, Baldessarini RJ, Faedda GL, et al. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991;48:1082-1088
4. Suppes T, Baldessarini RJ, Faedda GL, et al. Discontinuing maintenance treatment in bipolar manic-depression: risks and implications. Harvard Review of Psychiatry 1993;1:131-144
5. Baldessarini RJ, Suppes T, Tondo L. Lithium withdrawal in bipolar disorder: implications for clinical practice and experimental therapeutics research. American Journal of Therapeutics 1996;3:492-496
6. Baldessarini RJ, Tondo L, Suppes T, et al. Pharmacological treatment of bipolar disorder throughout the life-cycle. In: Shulman K, Tohen M, Kutcher S, eds. Bipolar Disorder Through the Life-Cycle. New York, NY: John Wiley & Sons; 1996:299-338
7. Suppes T, Baldessarini RJ, Motohashi N, et al. Risks of discontinuing maintenance treatment with psychotropic medicines. In: Rush J, ed. Modern Problems of Pharmacopsychiatry. Basel, Switzerland: Karger. In press
8. Müller-Oerlinghausen B, Müser-Causemann B, Volk J. Suicides and parasuicides in a high-risk patient group on and off lithium long-term medication. J Affect Disord 1992;25:261-270
9. Tondo L, Baldessarini RJ, Floris G, et al. Lithium maintenance treatment reduces risk of suicidal behavior in bipolar disorder patients. In: Gallicchio VS, Birch NJ, eds. Lithium: Biochemical and Clinical Advances. Cheshire, Conn: Weidner Publishing Group; 1996:161-171
10. Schou M. Is there a lithium withdrawal syndrome? an examination of the evidence. Br J Psychiatry 1993;163:514-518
11. Faedda GL, Tondo L, Baldessarini RJ, et al. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar mood disorders. Arch Gen Psychiatry 1993;50:448-455
12. Faedda GL, Baldessarini RJ, Tohen M, et al. Episode sequence in bipolar disorder and response to lithium treatment. Am J Psychiatry 1991;148: 1237-1239
13. Gelenberg AJ, Kane JM, Keller MB, et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 1989;321:1489-1493
14. Gitlin MJ, Swendsen J, Heller TL, et al. Relapse and impairment in bipolar disorder. Am J Psychiatry 1995;152:1635-1640
15. Coryell W, Endicott J, Maser JD, et al. Long-term stability of polarity distinctions in the affective disorders. Am J Psychiatry 1995;152:385-390
16. Molnar G, Pristach C, Feeney MG, et al. A pilot study of managed lithium discontinuation. Psychopharmacol Bull 1988;24:217-219
17. 7Li magnetic resonance spectroscopy. Biol Psychiatry 1994;36:511-516
18. Baldessarini RJ. Drugs and the treatment of psychiatric disorders: antidepressant and mood-stabilizing agents. In: Harden W, Rudin W, Molinoff PB, et al, eds. Goodman and Gilman's The Pharmacologic Basis of Therapeutics. New York, NY: McGraw-Hill; 1996:431-459
19. Baldessarini RJ. Lithium salts and other mood-stabilizing agents. In: Baldessarini RJ. Chemotherapy in Psychiatry: Principles and Practice. Cambridge, Mass: Harvard University Press; 1985:93-129
20. Wood AJ, Goodwin GM. A review of the biochemical and neuropharmacological actions of lithium. Psychol Med 1987;17:579-600
21. Lachman HM, Papolos DF. Abnormal signal transduction: a hypothetical model of bipolar affective disorder. Life Sci 1989;45:1413-1426
22. Manji HK, Potter WZ, Lenox RH. Signal transduction pathways: molecular targets for lithium's actions. Arch Gen Psychiatry 1995;52:531-543
23. Hyman, SE, Nestler EJ. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry 1996;153:151-162
24. Woods JH, Katz JL, Winger G. Abuse liability of benzodiazepines. Pharmacol Rev 1987;39:251-413
25. Lader M. Benzodiazepines: a risk-benefit profile. CNS Drugs 1994;1: 377-387
26. Rickels K, Schweizer E, Weiss S, et al. Maintenance drug treatment for panic disorder: short- and long-term outcome after drug taper. Arch Gen Psychiatry 1993;50:61-68
27. Mavissakalian M, Perel JM. Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Arch Gen Psychiatry 1992;49:318-323
28. McNamara JO. Drugs effective in the therapy of the epilepsies. In: Harden W, Rudin W, Molinoff PB, et al, eds. Goodman and Gilman's The Pharmacologic Basis of Therapeutics. New York, NY: McGraw-Hill; 1996: 461-486
29. Baldessarini RJ, Viguera AC. Commentary: neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 1995;52:189-192
30. Viguera AC, Baldessarini RJ, Hegarty JM, et al. Risk of discontinuing maintenance medication in schizophrenia. Arch Gen Psychiatry. In press
31. Baldessarini RJ, Tohen M. Is there a long-term protective effect of mood-altering agents in unipolar depressive disorder? In: Casey DE, Christensen AV, eds. Psychopharmacology: Current Trends. Heidelberg, Germany: Springer-Verlag; 1988:130-139
32. Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1991;47:1093-1099
33. Kupfer DJ, Frank E, Perel JM, et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992;49:769-773
34. Frank E, Kupfer DJ, Perel JM, et al. Comparison of full-dose vs half-dose pharmacotherapy in the maintenance treatment of recurrent depression. J Affect Disord 1993;27:139-145
35. Waters B, Lapierre Y, Gagnon A, et al. Determination of the optimal concentration of lithium for the prophylaxis of manic-depressive disorder. Biol Psychiatry 1982;17:1323-1329
36. Rosenbaum JF, Sachs GS, Lafer B, et al. High rates of relapse in bipolar patients abruptly changed from standard to low plasma lithium levels in a double-blind, controlled trial [abstract]. In: Proceedings of the 32nd Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU); May 1992; Key Biscayne, Fla. Bethesda, Md: National Institute of Mental Health; 1992